Maxcyte (DI) (MXCT)

 155.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 195.00
  • 52 Week Low: 107.50
  • Currency: UK Pounds
  • Shares Issued: 51.36m
  • Volume: 254,897
  • Market Cap: £79.60m

Regulatory News

Consolidation of Trading Lines 21-Feb-2020 07:00 RNS
AIM Block Admission Return / Total Voting Rights 20-Feb-2020 18:18 RNS
Grant Of Options 24-Jan-2020 16:31 RNS
Holding(s) in Company 22-Jan-2020 17:15 RNS
Holding(s) in Company 22-Jan-2020 17:11 RNS
Holding(s) in Company 22-Jan-2020 17:08 RNS
Trading Update 20-Jan-2020 07:00 RNS
New Executive Vice President and Trial Update 19-Dec-2019 07:00 RNS
Director/PCA transaction initial notification 16-Dec-2019 17:25 RNS
Agreement with KSQ Therapeutics 04-Dec-2019 07:00 RNS
Vor Biopharma Clinical and Commercial License 21-Nov-2019 07:00 RNS
Result of AGM 01-Nov-2019 13:04 RNS
MaxCyte Advances Phase I Clinical Trial 24-Oct-2019 07:00 RNS
Notification of AGM and Audit Declaration 08-Oct-2019 07:00 RNS
Editas Clinical and Commercial License Agreement 07-Oct-2019 07:00 RNS
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Maxcyte (DI) Market Data

Currency UK Pounds
Share Price 155.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 195.00
52 Week Low 107.50
Volume 254,897
Shares Issued 51.36m
Market Cap £79.60m

Maxcyte (DI) Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 2
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Maxcyte (DI) Dividends

No dividends found

Trades for 28-Feb-2020

Time Volume / Share Price
16:26 1,000 @ 150.85p
15:07 5,000 @ 159.85p
15:42 2,675 @ 150.85p
13:52 250,000 @ 155.00p
11:38 10,000 @ 151.85p

Maxcyte (DI) Key Personnel

CEO Doug Doerfler
CFO Ron Holtz

Top of Page